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Abstract. Sixteen recipients of neonatal liver grafts were 
compared with 114 contemporaneous pediatric recipients 
of grafts from older donors. Graft and patient survival 
were worse in the neonatal group although the differences 
were not statistically significant. Patients with neonatal 
livers who had no technical complications required a 
longer time postoperatively to correct jaundice and a pro-
longed prothrombin time. These functional differences 
were limited to the 1st postoperative month and the end 
result was the same as with liver transplantation from 
older donors. 
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The available liver donor pool has been expanded with 
the use of grafts from older donors [13.19]. In liver trans- I 
plantation in infants and small children. the number of 
candidates far exceeds organ availability, resulting in sig-
nificant mortality of patients on waiting lists [4, 23]. 
Possible options include the use of reduced-size or split 
liver grafts [1. 2. 7, 8. 12] and the use of livers from neo-
natal donors. Results of our experience with the use of 
neonatal livers for transplantation in very small pediatric 
recipients is herein reported. A minimum of 14 months 
follow-up is provided. 
Patients and methods' 
The charts of all patients who underwent primary liver transplanta· 
tion at the Children s Hospital of Pittsburgh under cyclosporine-ste-
roid therapy and had liver grafts preserved with University of Wis-
consin solution [7J were reviewed. These transplants took place 
between October 1l)87. when University of Wisconsin solution be-
(arne a\ailahle to us for clinical use. and September 1lF~9K when 
FK SOb was introduced as the primary immunosuppressive agent 
1201. Follow-up is provided to December 31. 19YO. and consequently 
ranged from 1.+ to .19 months (median 25 months). 
()ne hundrt:d and thirty patients were studied: their pnmary liver 
dlsc:ast: is shown In Table I. The recipient age ranged from I to 
20.+ months (mean 51.1 ± .+.9 months 1 and the male/female ratio was 
7/0. 
( ITrt'sl'olll/1'IIC(, II): T. E. Starzl 
.. 
Two groups were identified depending on the age of the donor: 
group A were recipients of neonatal (age 28 days or less) donor 
grafts (n = 16) and group B recipients of grafts from older donors 
(n = 114). In case of retransplantation. the age of only the primary 
donor was considered. 
Donor age. body weight. prothrombin time. serum total bilirubin 
and alanine aminotransferase (ALT) were recorded. These labora-
tory data were missing for 10 donors in group B. 
An accounting of the donors and recipients in group A is given in 
Table 2. Anoxic injury due to birth asphyxia was the most common 
cause of donor death (75 % ). Thirteen donors (81 % ) were less than 
2 weeks old and all weighed less than 5 kg. All but two recipients 
were less than 1 year old and all weighed less than 10 kg. Biliary atre-
sia was the underlying disease in 11 patients. Nine of them (82 % ) 
had had previous failed portoenterostomies. 
A summary of the donor and recipient demographic data in 
group B is shown in Table 3. 
The surgical techniques employed for graft recovery and trans-
plantation have been reported previously [14. 16. 18]. Organ preser-
vation period (cold ischemic time) ranged from 6.7 h to 17.9 h 
(9.4 ± 1.4 h) in group A and from 5.1 h to 29.1 h (8.5 ± 0.5 h) in 
group B. No statistical differences were noted between the two 
groups. 
Heparin (50 IV/kg subcutaneously twice a day), aspirin (20 mg 
forbodyweight < 8 kg,40 mgfor8-15 kg,orSO mgfor > 15 kg. orally. 
once a day) and Persantine (dipyridamole. 6.25 mg for body weight 
< 12 kg or 12.5 mg for ~ 12 kg, orally, twice a day) were administered, 
unless bleeding occurred, when the prothrombin time was less than 
20 s throughout the hospitalization. All ofthe patients in group A re-
ceived parenteral hyperalimentation including vitamin K immedi-
ately postoperatively until they tolerated oral feeding well. 
Doppler ultrasonography was performed routinely within 24 h 
postoperatively and was repeated when a complication was sus-
pected. Absence of arterial pulsations on two consecutive ultra-
Table L Indications for liver transplantations (n = 130) 
Diagnosis 
Biliary atresia or other type of biliary cirrhosis 
Cirrhosis secondary to metabolic disorders 
Chronic hepatitis 
Postnecrotic cirrhosis 
Tumors 
Budd-Chiari syndrome 
Total 
No. of patients 
S5 
15 
13 
l) 
o 
LlO 
'. 
~MS 
Table 2. Donor and recipient patient characteristics in group A (neonatal donors). ICH.lntracerehral hemorrhage: SIDS. sudden infant death 
~yndrome: BA. biliary atresia: ATD. aI-antitrypsin deficiency: NH. neonatal hepatitis: AS. Alagille's syndrome: PNC. post necrotic cirrhosis 
Donor Recipient 
Patient Age Body weight Cause of Age 
no. (davs) (kg) death (months) 
1'\ 3.7 Anoxia 7 
~ ~o 2.3 Anoxia 6 
.' 12 3.2 ICH 9 
~ ~U ~Kl Anoxia 5 
5 X 3.3 SIDS 7 
0 3 2.7 Anoxia 2 
7 ., 2.7 Anoxia 13 .. 
B 5 2.6 ICH 7 
9 3 3.7 ICH 9 
10 16 3.2 Anoxia 2 
11 6 4.5 Anoxia 12 
12 2 3.2 Anoxia 11 
13 6 3.3 Anoxia 19 
14 12 3.2 Anoxia 5 
15 3 3.3 Anoxia 5 
16 4 3.4 Anoxia 9 
Mean 5.6 3.3 B.O 
SEM 1.B 0.1 1.1 
a Previous portoenterostomy 
b Received third graft 
Table 3. Summary of donor and recipient demographic data in 
group B (nonneonatal donors) 
Donor 
Age (years) 
Body weight (kg) 
Recipient 
Age (years) 
Body weight (kg) 
Sex (male:female) 
Mean±SEM 
4.9±0.4 
14.0± 1.1 
4.B±0.4 
IB.O±O.1 
62:52 
(32 days to 42 years) 
(2.7...{jB.2 kg) 
(1 month to 17 years) 
(4.l-S4.3 kg) 
• sound examinations established the diagnosis of arterial thrombosis. 
In some patien ts, this diagnosis was made by arteriography or during 
surgical exploration. 
Body weight of.the patients in group A was recorded preopera-
tively and followed for the duration ofthe study. Control values were 
obtained from the National Center for Health Statistics percentiles 
[5]. 
The patients in each group who survived and had a technically 
uncomplicated postoperative course were identified (group Al and 
group Bl,respectively). Ten patients in group Bl were excluded due 
to incompleteness of data. Body weight, prothrombin time, serum 
total bilirubin and ALTpreoperatively and postoperatively at days 1 
through 7 and.days 14 and 30 were recorded. The prothrombin time 
values were not in all cases available for postoperative days 14 and 
30. In these cases. the mean of the immediately preceding and the 
following available values were entered. 
All data are presented as mean ± the standard error of the mean 
(i + SEM); differences in the mean were tested using Student's t test 
or X2 for comparison procedure. Actuarial survival rates were calcu-
lated by the method of Kaplan-Meier. A Pvalue ofless than 0.05 was 
considered to be statistically significant. 
Results 
Out of all the 130 patients. 35 died (27 % ), 6 in group A 
and 29 in group B. The primary causes of death in these 
35 patients are shown in Table 4. 
Body weight Sex Liver disease Retrans- Outcome 
(kg) plantation 
5.0 M BA No Alive 
R.I M BA No Dead 
7.3 M Am Yes" Alive 
5.7 M BA' Yes Dead 
5.9 F BA' Yes Dead 
2.7 M NH No Dead 
7.4 F BA' No Alive 
5.5 F BA" No Dead 
5.4 F BAa Yes Dead 
5.B M Tyrosinemia No Alive 
6.3 M BA' Yes Alive 
6.3 M BA' No Alive 
7.5 M AS No Alive 
3.6 F PNC No Alive 
6.5 F BA" No Alive 
6.7 M BAa No Alive 
6.0 
0.3 
Table 4. Postoperative complications and deaths in 130 patients. 
HATX, hepatic artery thrombosis; PVTX, portal vein thrombosis 
Complications No of patients (deaths) 
Group A GroupB 
(n= 16) ,(n=114) 
Vascular 
HATX' 5 (2) 10 (4) 
PVTX I (1) 2 (0) 
Portal vein rupture 0(0) 1 (1) 
Vena caval occlusion 0(0) 1 (1) 
Biliary' 0(0) 11 (0) 
Others 
Perioperative deathb 1 (1) 6 (6) 
Graft nonfunction 1 (1) 6 (3) 
Bacterial sepsis 0(0) 5 (5) 
Viral infection 1 (1) 4 (4) 
Rejection 0(0) 3 (1) 
Malignancy 0(0) 3 (3) 
Pulmonary hypertension 0(0) 1 (1) 
Total 9 (6) 53 (29) 
, The incidences are significantly different between the two groups 
(P<0.05) 
b Complications including intra-operative death or brain death 
Actuarial survival rates at 1,2, and 3 years postopera-
tively were 68%, 68%, and 51 % respectively in group A 
and 76 %, 74 % and 74 % in group B (Fig. 1, top). Actua-
riall-, 2-, and 3-year graft survival rates were 56 %,56 %, 
and 38 % respectively in group A and 70 %, 68 %, and 
67 % in group B (Fig. 1. bottom). None of the differences 
in patient or graft survival achieved statistical significance 
(P = 0.37 and 0.19, respectively). 
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Fig.I. a Cumulative patient survival rates in group A (n = 16: donor 
age S 2R days) and group B (n = 114: donor age> 28 days). The dif· 
ference was not statistically significant (P = 0.37). b Cumulative 
graft survival rates in group A and group B. The difference was not 
statistically significant (P = 0.19).-Group A, --- group B 
Five patients (31 %) in group A underwent retrans-
plantation. due in three patients to hepatic artery throm-
bosis, in one to primary nonfunction, and in one to he-
patitis (Table 2). Two of them were alive at the end of 
follow-up, including one patient who had a third graft. 
Nineteen (16%) patients in group B underwent retrans-, 
plantation, due in ten patients to hepatic artery throm-
bosis, in six patients to primary nonfunction, and in three 
patients to rejection. Of them nine were alive at the end of 
follow-up. Three patients received a third graft: all three 
died. 
Perioperative complications are presented in Table 4. 
Hepatic artery thrombosis was the most common in 
group A and its incidence was significantly higher than in 
group B (31 %, n =5 vs 9%, n= 10, P=O.027). Of the 
15 patients who developed hepatic artery thrombosis nine 
survived. three in group A, of them one without retrans-
plantation. and six in group B, of them two without re-
transplantation. Three patients developed portal vein 
thrombosis: one in group A and two in group B. The 
patient in group A died as a result of this complication. 
Both patients in group B were alive. one after successful 
thrombectomy and one other after distal splenorenal 
shunt. One patient in group B developed portal vein rup-
ture due to infection. Biliary complications not associated 
with hepatic artery thrombosis were more common in 
group B. but the difference was not significant (p = 0.4). 
The biochemical profile of the donors in the two groups 
was similar (mean ALT: 64.2 ± 22.2 vs 79.3±2.1, mean 
prothrombin time 10.5 ± 0.9 vs 12.8 ± 0.4. respectively) 
except for the total bilirubin which was 1.7 + 0.5 (0.4-
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Fig.2. a Serum total bilirubin, * P < 0.05. b Prothrombin time. 
* P < 0.05, ** P < 0.01. c ALT (alanine aminotransferase) in groups 
Al and BI (patients without complications).-o-Group AI, n = 7: 
--group B1.n =51 
15 
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Fig. 3. Body weight changes in eight patients in group A who sur· 
vived with their primary grafts during the observation period. Dotted 
line denotes 50th percentile body weight from the study of the 
National Center for Health Statistics Percentiles [51 
208 
8.4)mg/dl in groupA and 0.7±0.1 (O.l-6.7)mg/dl in 
group B (P < 0.05). 
Perioperative biochemical values were compared be-
tween groups Al (1/ = 7) and B I (n = 51. Fig. 2). Serum total 
bilirubin levels in days 1 through 14 and prothrombin time 
for days 1 through 4 were significantly higher in group AI. 
Serum ALTlevels were not significantly different. 
Eight of the patients in group A were alive with their 
primary grafts. The body weight at the time of transplan-
tation was below the 5th percentile in six of them. at the 
5th-10th percentile in one, and at the 25th-50th percentile 
in the eight patient. All patients gained weight during the 
observation period. While three patients remained at the 
5th percentile, all others upgraded (Fig.3). 
Discussion 
There are two features of neonatal liver transplantation 
requiring special consideration: technical difficulties due 
to the small size of the grafts [4], and functional perfor-
mance, because neonatal livers are thought to be imma-
ture [3,9, 11]. 
The increased incidence of hepatic artery thrombosis 
in the patients with neonatal transplants can be seen as 
a reflection of the technical difficulties encountered [10, 
17, 21]. Interestingly, other complications related to the 
venous or biliary reconstructions did not occur with a 
greater frequency in the neonatal group. The possible role 
of immaturity of the graft and delayed function may also 
be related to hepatic artery thrombosis because of de-
creased or absent protein C synthesis by the newly trans-
planted liver [6]. 
Of the liver function tests referred to here, the pro-
thrombin time is representative of the synthetic function 
of the liver and the total bilirubin of its ability to clear 
metabolic waste products. It appears that neonatal liver 
grafts gain normal synthetic function within 4-5 qays after 
transplantation. Older donor grafts normally function im-
mediately after transplantation. The ability to clear bili-
rubin is even more slowly regained: total bilirubin did not 
return to normal for 1 month, as compared to 1 week in 
grafts from older donors. Interestingly, after this slow re-
covery, which appears to be characteristic of the neonatal 
donor livers, the ultimate result is indistinguishable from 
that of livers from older donors. 
• Growth of the patients.with liver grafts from neonatal 
donors appears to be similar to that observed previously in 
pediatric liv~r transplant recipients [15, 22]. 
In conclusion. if successful. neonatal liver transplanta-
tion can have equally good results as transplantation with 
livers from older donors. 
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